ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
ERDERA will launch its Clinical Trial Call (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
Rare disease researchers, clinicians, patient advocates and data experts are invited to help shape four new IRDiRC activities linked to the new IRDiRC Roadmap, with applications closing on 20 February 2026.
